Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

elbion GMBH

Division of Acorda Therapeutics Inc.
www.elbion.com

Latest From elbion GMBH

Deals Shaping the Medical Industry (11/2008)

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Windhover's Strategic Transactions Database, providing comprehensive transaction coverage from 1991 to the present.

Deals Shaping the Medical Industry (3/07)

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Windhover's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.

The A-List: 2005's Trend-Shaping Series A Financings

2005's top early stage venture financings reflect a drive for size and experience on the biotech side, and the demand for less-invasive procedures in the device world. Start-Up lists the top ten Series A rounds of 2005.
BioPharmaceutical Medical Device

No Dilution Necessary: The Promise of Project Financing

Project financing, claim its proponents-in particular Symphony Capital-offers an alternative to highly dilutive equity offerings, preserving the upside from the development of a successful product for the biotech. That's true, though this expensive capital isn't for everyone. Yet as Big Pharma's productivity challenge deepens, project financing is helping to swing the balance of power further towards small companies.
BioPharmaceutical Strategy
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Immune Disorders
  • Inflammation
  • Neurology, Nervous System
  • Alias(es)
  • 4 AZA Bioscience NV
  • elbion AG
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Germany
  • Parent & Subsidiaries
  • Acorda Therapeutics Inc.
  • Senior Management
  • Bernd Kastler, CEO
    Thomas Taapken, CFO
    Thomas Kronbach, CSO
  • Contact Info
  • elbion GMBH
    Phone: (49) 351 404 33 308
    Meißner Str. 191
    Radebeul, 01445
    Germany
Advertisement
Advertisement
UsernamePublicRestriction

Register